Rapacuronium

Summary

Rapacuronium (CHEMBL1201352) is an approved small molecule that acts as a muscle-type nicotinic acetylcholine receptor antagonist.

At a glance

• Status: FDA-approved
• Modality: Small molecule
• Chemistry: 597.9 Da · C37H61N2O4+

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201352
Name	Rapacuronium
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5311399
Molecular formula	C37H61N2O4+
Molecular weight	597.9
InChIKey	HTIKWNNIPGXLGM-YLINKJIISA-N

SMILES: CCC(=O)O[C@H]1[C@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)OC(=O)C)N5CCCCC5)C)C)[N+]6(CCCCC6)CC=C

IUPAC name: [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-acetyloxy-10,13-dimethyl-2-piperidin-1-yl-16-(1-prop-2-enylpiperidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] propanoate

Also known as: Rapacuronium cation, Rapacuronium ion

Parent form; salt/anhydrous children: CHEMBL1200549

Patent coverage: 8 distinct patent families (10 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Mechanism of action (ChEMBL curated)

Mechanism of action	Action type	Target	Target type
Muscle-type nicotinic acetylcholine receptor antagonist	ANTAGONIST	Muscle-type nicotinic acetylcholine receptor	PROTEIN COMPLEX GROUP

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 — no curated potent assays (common for biologics/antibodies and for inorganic, imaging, or reference compounds).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Predicted targets — Sugi Predict

This molecule is SureChEMBL compound SCHEMBL16977930 — see its predicted protein targets + similar patent compounds on Sugi Predict.

Indications & clinical

Indications

No ChEMBL drug-indication records for this molecule.

Regulatory approval & mechanism (DrugCentral)

Approved: FDA. Curated mechanism: ANTAGONIST · 5 MOA targets of 5 total (P02708, P07510, P11230, Q04844, Q07001).

DrugCentral (CC BY-SA): authoritative regulatory-approval status + curated mechanism. The drug’s full target set is in Targets above.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

MeSH pharmacological classification

MeSH note: 16-N-allyl-17-beta-propionate analog of vecuronium.

Pharmacological action: Neuromuscular Nondepolarizing Agents.

Broader MeSH heading: Vecuronium Bromide.

MeSH supplementary concept C082938 “rapacuronium” — exact-name match.

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Adverse-event reports (FAERS)

2 reports across 1 FAERS drug-name record; 1 distinct MedDRA reaction.

openFDA FAERS — spontaneous post-marketing reports. Co-occurrence, not causation: reports are voluntary, unverified, and confounded by indication and reporting bias (the drug’s own indication often appears as a ‘reaction’). PRR is a disproportionality heuristic (reaction rate for this drug vs the FAERS background), NOT a risk estimate. Counts are pooled across the drug’s name records.

Most-reported events

Serious = reports flagged serious (death / life-threatening / hospitalisation / disability / other medically important).

1 reactions by report volume:

Reaction (MedDRA PT)	Reports	Serious	PRR
bronchospasm	2	0 (0%)	1464.0×

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).